Overview
Circulating myostatin exists in a latent complex with its N-terminal propeptide and LTBP-3 on fibrillin microfibrils. Proteolytic activation (via BMP-1/tolloid metalloproteinases) releases the mature dimer into the active pool. Mature myostatin binds ActRIIB with high affinity (Kd ~10 nM), and the resulting signaling cascade modulates both myoblast proliferation (G1 arrest via p21 upregulation) and differentiation (MyoD/myogenin suppression). In muscle fibers, it promotes proteasomal degradation via the ubiquitin-proteasome system. Systemic inhibition via anti-ActRIIB antibodies (e.g., ACE-031) showed robust muscle hypertrophy but also off-target effects on bone and vascular telangiectasia in clinical trials, highlighting the pleiotropic role of this pathway.
Proposed mechanism
Myostatin binds to activin type II receptors (ActRIIA and ActRIIB) on muscle cells, triggering phosphorylation of SMAD2/3 transcription factors via ALK4/5, which suppresses the expression of genes required for muscle protein synthesis and myogenesis. It also downregulates IGF-1/Akt/mTOR signaling, reducing anabolic drive in skeletal muscle. Loss-of-function mutations in MSTN—observed in double-muscled cattle, whippets, and rare human cases—produce dramatic hypermuscular phenotypes, validating its role as a muscle growth brake.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
McPherron AC et al. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member
· Nature, 387:83-90. doi:10.1038/387083a0 · 1997
- [2]
Schuelke M et al. Myostatin mutation associated with gross muscle hypertrophy in a child
· N Engl J Med, 350:2682-2688. doi:10.1056/NEJMoa040933 · 2004
- [3]
Wagner KR et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy
· Ann Neurol, 63(5):561-571. doi:10.1002/ana.21338 · 2008
- [4]
Latres E et al. Activin A more prominently regulates muscle mass in primates than does GDF8
· Nature Communications, 8:15153. doi:10.1038/ncomms15153 · 2017
- [5]
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults
· JAMA Network Open, 4(10):e2033604. doi:10.1001/jamanetworkopen.2020.33604 · 2021
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.